Wed, Aug 20, 2014, 1:04 PM EDT - U.S. Markets close in 2 hrs 56 mins

Recent

% | $
Quotes you view appear here for quick access.

Genetic Technologies Limited Message Board

  • commoncentsinvestor commoncentsinvestor Sep 18, 2011 11:12 PM Flag

    I can't imagine what the

    share price of GENE might be if they actually did Press Releases in the U.S. of all the positive things that are going on with the company.

    Just in the last few weeks they have

    1. Settled with Attomol GmbH
    2. Settled with Beckman Coulter, Inc.
    3. Settled with Clinical Data, Inc.
    4. Added another Monsanto license
    5. Reported full year earnings with 111% Revenue increase, Cash flow positive, and their first ever yearly profit.

    NONE OF THE ABOVE has been issued in any Press Release in the United States.

    While I am a huge GENE fan and have great expectations for the future of the company, this lack of providing information is really irresponsible behavior on the part of the company towards its U.S. shareholders.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • three of those items you listed happened last year...the settlements with Beckman Coulter, Clinical Data and the Monsanto License all happened in August of last year. Not in the last few weeks like you mentioned.

    • Those are material events and should be reported. I think that the problem with this stock is the following:

      It's all about perception and share placement. The company is doing well, they are by most accounts on the verge of transitioning into what appears to be a major company. They are not there yet and who is going to accumulate this stock when they know that GENE just raised 12.2 million at around $5.50? Wall Street doesn't make others wealthy, they make themselves wealthy. I am a buyer of this stock, but, until the overhang issue is resolved and GENE connects with a major firm in the U.S. the stock will languish in the 5-9 range. A major announcement would be helpful. The only question that I think we should all be asking is: Why does a company that is on the verge of major litigation settlements and profitability, dilute its stock at such a relative low market cap? There are many ways to fund a roll out of a new product, why did they choose that way????

    • Thank You Commoncent for all the news updates I did not realized happen ;-)

 
GENE
0.64-0.010(-1.52%)12:45 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.